Home|Journals|Articles by Year|Audio Abstracts

Original Article

Pak J Nucl Med. 2013; 3(1): 37-43

Study of normal biodistribution and uptake patterns of novel anticancer radiopharmaceutical complex 99mTc-Methotrexate

Sajjad Ahmed Memon, Naeem Ahmed Laghari, Sadaf Tabasum Qureshi, Fayaz Ahmad, Atif Masood, Shahid Iqba.


Objective: Methotrexate (MTx) is an anticancer agent used in the treatment of various cancers. The objective of this study was to document the biodistribution of 99mTc-labelled Mtx (99mTc-MTx) in normal subjects and patients with breast cancers. Methods: We prepared the 99mTc-MTx kit by a direct labelling method and studied its biodistribution in volunteer subjects and patients with breast carcinoma breast. This clinical study was preceded by animal trials. Results: The normal biodistribution pattern in humans was characterized by nonspecific uptake in the body with the 99mTc-MTx behaving like a blood pool agent with no evidence of specific organ uptake. The kidneys were seen to be the main route of excretion. Biodistribution data of patients with carcinoma breast showed excellent tracer uptake in the tumour and showed no other nonspecific tracer uptake. Conclusion: This initial clinical trial showed that 99mTc-labelled anticancer drug can be successfully used for tumour scintigraphy, which appears to be a major breakthrough as this method of labelling and scanning may be useful in future tumour staging, calculating the sensitivity of tumours to certain anticancer agent and response evaluation during chemotherapy.

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Review(er)s Central
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.